Novartis presents updated data that reinforce the efficacy and safety of Kisqali® (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer
- Details
- Category: Novartis
Novartis announced today updated findings from the Phase III MONALEESA-2 study that reinforce the efficacy and safety of Kisqali® (ribociclib) plus letrozole in postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.
At ASCO 2017 clinicians present new evidence about Watson cognitive technology and cancer care
- Details
- Category: Business
IBM Watson Health (NYSE: IBM) and its collaborators today unveiled data that will be presented at ASCO 2017, demonstrating the clinical utility of Watson for Oncology trained by Memorial Sloan Kettering as well as Watson for Clinical Trial Matching (CTM). IBM also announced the latest updates on adoption of Watson oncology offerings,
Anyone can become more curious. Is that true?
- Details
- Category: Merck Group
Merck, a leading science and technology company, today announced the start of an experiment entitled "Anyone can become more curious". Driven by the company’s curiosity initiative, which measured and described curiosity in detail in various countries such as the United States, China and Germany - the question now is if and how one can increase curiosity so as to ultimately lead to more or better science-driven behavior.
Array BioPharma and Bristol-Myers Squibb announce strategic collaboration
- Details
- Category: Bristol-Myers Squibb
Array BioPharma (Nasdaq:ARRY) and Bristol-Myers Squibb Company (NYSE:BMY) today announced the companies have entered into a clinical research collaboration to investigate the safety, tolerability and efficacy of Array's investigational MEK inhibitor, binimetinib in combination with Bristol-Myers Squibb's Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a potential treatment for metastatic colorectal cancer in patients with microsatellite stable tumors.
FDA Advisory Committee recommends approval of Pfizer's proposed biosimilar to Epogen® / Procrit® across all indications
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of the Company's proposed epoetin alfa biosimilar across all indications. This marks the first time a biosimilar erythropoiesis-stimulating agent (ESA) has been recommended for approval by a U.S. FDA Advisory Committee.
New data at ATS add to the body of evidence for Roche's Esbriet (pirfenidone) in idiopathic pulmonary fibrosis (IPF)
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new retrospective data analyses for Esbriet® (pirfenidone) in idiopathic pulmonary fibrosis (IPF) that were presented at the American Thoracic Society (ATS) 2017 International Conference. Three post hoc analyses of the pooled phase III ASCEND and CAPACITY studies indicated that IPF patients treated with Esbriet may experience a reduction in the risk of death,
Sanofi and Regeneron announce FDA Approval of Kevzara® (sarilumab) for the treatment of moderately to severely active rheumatoid arthritis in adult patients
- Details
- Category: Sanofi
Sanofi and Regeneron Pharmaceuticals, Inc. have announced the U.S. Food and Drug Administration (FDA) approval of Kevzara® (sarilumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX).
More Pharma News ...
- AstraZeneca enters agreement with Recordati for Seloken in Europe
- Novartis receives positive CHMP opinion for first-line use of Zykadia® in ALK-positive advanced non-small cell lung cancer (NSCLC)
- 100 healthy years - are kids prepared?
- Novartis Foundation and partners launch initiative to tackle hypertension and its root causes in low-income urban communities
- Boehringer Ingelheim inaugurates world-class biopharmaceutical manufacturing facility in China
- Imfinzi significantly reduces the risk of disease worsening or death in the Phase III PACIFIC trial for Stage III unresectable lung cancer
- Sangamo Therapeutics and Pfizer announce collaboration for Hemophilia A gene therapy